Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization
about
Rational combinations of immunotherapeutics that target discrete pathways.Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaContribution of interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 ligand pathways to the development of a pathological T-cell response in IL-10-deficient mice.Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population.B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.CD86 has sustained costimulatory effects on CD8 T cells.Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.Costimulatory and coinhibitory receptors in anti-tumor immunityExpression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours.CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response.Irradiation up-regulates CD80 expression through induction of tumour necrosis factor-alpha and CD40 ligand expression on B lymphoma cells.Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells.Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.
P2860
Q33606144-AED801B2-B9E8-45B6-A894-8D38386B73AEQ33840446-49546AB4-A91A-4C1C-9D7D-7C511B793192Q34262167-29A725F7-593F-4BD6-A812-69508EABFDF3Q35079386-0B810BCE-97CB-42EB-84EA-4166E0D4649AQ36292507-2B31EB7E-88D8-40FA-9F4A-9945C171ADCBQ36368203-45440501-B817-4257-9240-FDD0C715F22FQ36851775-049D3C9F-F3B7-4102-8177-FF48A37D1A42Q37069249-33FE75F9-FC95-41F4-B662-E331AA53CADEQ37255184-D5C6AEF8-91CF-4591-A39F-EC2C16F9C335Q37474920-2D8466A4-67CF-4C71-B3E3-65C482011CAFQ39710346-18A2D2AE-7B4F-49F1-8F73-2E50546EB1EDQ39813239-74037C06-05D9-43D1-A2A0-416357B920F4Q40614567-DDB9678D-3F79-405F-99C8-875080B45C57Q44052198-7AFAFB8C-79FB-42EC-B1D7-E647C4375515Q44899128-4C07BC52-581F-47E1-B879-5EF7C607D462Q45873362-29446EE0-4073-4F19-AEC9-736592BA3BB7
P2860
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization
description
im April 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 1996
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 1996
@uk
name
Tumor rejection requires a CTL ...... for active tumor immunization
@en
Tumor rejection requires a CTL ...... for active tumor immunization
@nl
type
label
Tumor rejection requires a CTL ...... for active tumor immunization
@en
Tumor rejection requires a CTL ...... for active tumor immunization
@nl
prefLabel
Tumor rejection requires a CTL ...... for active tumor immunization
@en
Tumor rejection requires a CTL ...... for active tumor immunization
@nl
P2093
P1476
Tumor rejection requires a CTL ...... for active tumor immunization
@en
P2093
C Uyttenhove
F Fallarino
T F Gajewski
P304
P407
P577
1996-04-01T00:00:00Z